Form 8-K

8-K — Calidi Biotherapeutics, Inc.

Accession: 0001493152-26-013236

Filed: 2026-03-27

Period: 2026-03-27

CIK: 0001855485

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001855485

2026-03-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): March 27, 2026

CALIDI

BIOTHERAPEUTICS, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-40789

86-2967193

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

4475

Executive Drive, Suite 200,

San

Diego, California

92121

(Address

of principal executive offices)

(Zip

Code)

(858)

794-9600

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title

of Each Class

Trading

Symbol(s)

Name

of Each Exchange on Which Registered

Common

stock, par value $0.0001 per share

CLDI

NYSE

American LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

March 27, 2026, Calidi Biotherapeutics, Inc. (the “Company”) issued a press release announcing certain financial results

for the fourth quarter and full year ended December 31, 2025, and certain recent corporate developments. A copy of the press release

is incorporated herein by reference and is furnished as Exhibit 99.1.

The

information under this Item 2.02 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18

of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such

section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the

“Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item

7.01 Regulation FD Disclosure.

The

information under Item 2.02 above is incorporated herein by reference.

filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality

of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information in this Item 7.01

disclosure, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the

Exchange Act, or otherwise subject to the liabilities under that section. In addition, the information in this Item 7.01 disclosure,

including Exhibit 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended,

or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Description

99.1

Press Release dated March 27, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

CALIDI

BIOTHERAPEUTICS, INC.

Dated:

March 27, 2026

By:

/s/

Andrew Jackson

Name:

Andrew

Jackson

Title:

Chief

Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Calidi

Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

Announced

partnership with Australian CRO to accelerate initiation of CLD-401 clinical trial

The

Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and analytical

approaches for CLD-401 are in alignment with FDA guidance; Calidi expects to file an IND by end of 2026

Partnered

with Matica Bio around the GMP manufacturing of CLD-401

Presented

new data on in situ T-cell engagers (TCEs) at 2026 AACR-IO conference

Raised

$6.5 million in public offering and ATM sales

SAN

DIEGO, March 27, 2026 — (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the

“Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter

and full-year 2025 operating and financial results and reviewed recent business highlights.

“We

are extremely excited about the continued progress at Calidi,” said Eric Poma, PhD, CEO of Calidi Biotherapeutics. “We continue

to advance CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board

to aid those efforts. We have also expanded what the RedTail platform can do with our new approach of in situ T-cell engagers.”

Fourth

Quarter 2025 and Recent Corporate Developments

- Partnered

with Avance Clinical, a full-service contract research organization (CRO) with a proven track

record and experience in obtaining regulatory approval and clinical trial initiation in Australia.

The partnership is focused on rapidly initiating a first-in-human clinical trial for CLD-401

in Australia. CLD-401, the Company’s lead asset, is a systemically delivered oncolytic

virus that replicates only in tumor cells. CLD-401 induces high concentrations of IL-15 superagonist

(IL15 SA) expression in the tumor microenvironment while limiting peripheral exposure.

- In

parallel, Calidi is pursuing an IND filing with the FDA by the end of 2026. Calidi has interacted

with the FDA around the Company’s manufacturing and analytical approaches through its

Type D meeting request process. The feedback it has received from the agency supports the

use of this process for the clinical development of CLD-401.

- Partnered

with Matica Bio, a leading CDMO in the field of oncolytic virus manufacturing, for the GMP

manufacturing of CLD-401. Matica has successfully executed multiple oncolytic virus programs

at its state-of-the-art, purpose-built GMP facility in College Station, Texas. That facility

was designed specifically to support complex viral vector modalities like CLD-401.

- Presented

data demonstrating the expression of an in situ T-cell engagers (TCEs) for solid tumors and

the simultaneous expression of a T-cell activating agent (e.g., IL-15 SA) through its systemically

delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference. High expression

of in situ TCE coincident with expression of a T-cell activator in the TME may overcome the

traditional limitations of TCEs in solid tumor.

- Raised

$6.0 million in gross proceeds from an underwritten public offering with new and existing

investors in Q1-2026 and $0.5 million in gross proceeds from the sale of stock under our

ATM in Q4-2025, strengthening the balance sheet and extending Calidi’s cash runway.

Fourth

Quarter 2025 Financial Results

The

company reported a net loss attributable to common stockholders of $4.1 million, or $0.57 per share, for the three months ended December

31, 2025, compared to a net loss attributable to common stockholders of $4.1 million, or $3.23 per share, for the same period in 2024.

Research

and development expenses were $2.4 million for the three months ended December 31, 2025, compared to $1.8 million for the comparable

period in 2024, respectively.

General

and administrative expenses were $2.1 million for the three months ended December 31, 2025, compared to $2.2 million for the comparable

period in 2024, respectively.

Full

Year 2025 Financial Results

The

company reported a net loss attributable to common stockholders of $25.6 million, or $5.95 per share, for the year ended December 31,

2025, compared to a net loss attributable to common stockholders of $23.8 million, or $35.70 per share, for the year ended December 31,

2024.

Research

and development expenses were $9.7 million for the year ended December 31, 2025, compared to $8.9 million for the year ended December

31, 2024, respectively.

General

and administrative expenses were $10.5 million for the year ended December 31, 2025, compared to $12.9 million for the year ended December

31, 2024, respectively.

The

company had approximately $5.6 million in cash and $0.2 million in restricted cash as of December 31, 2025, compared to $9.6 million

in cash and $0.2 million in restricted cash as of December 31, 2024.

About

Calidi Biotherapeutics

Calidi

Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential

to deliver genetic medicines to distal sites of disease. The company’s proprietary Redtail platform features an engineered enveloped

oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield

the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic

medicine(s) to metastatic locations.

CLD-401,

the lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer,

and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the Redtail platform including

its novel approach to incorporate in situ T-cell engagers in solid tumors.

Calidi

Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s

Corporate Presentation here.

Forward-Looking

Statements

This

press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States

Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,”

“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”

“possible,” “potential,” “predicts,” “project,” “should,” “towards,”

“would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement

is not forward-looking. These forward-looking statements include, but are not limited to, the Company’s plans strategies, priorities

and key operational initiatives for fiscal year 2026, including the Company’s plan to submit an Investigational New Drug (“IND”)

application by the end of 2026, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and

statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements

contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential

effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those

set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that

Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of

clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following

more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval

for some or all of its therapeutic candidates; and, with respect to the Company’s fiscal year 2026 initiatives, including the timing

and ability to submit an IND application by the end of 2026, the risk that actual results may differ materially due to, among other things,

the timing, cost and results of research and development activities and preclinical studies; interactions with, and the timing and substance

of feedback from, regulatory authorities (including that any preliminary interactions with the FDA may not be indicative of future outcomes

or regulatory success); changes in applicable laws or regulations; manufacturing and supply chain matters; the availability of capital

and other resources; and changes in business, market, economic or competitive conditions. Other risks and uncertainties are set forth

in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s

annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the

SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the

date of this press release or to reflect the occurrence of unanticipated events.

Contacts:

For

Investors and Media:

Dave Gentry, CEO

RedChip Companies, Inc.

1-407-644-4256

CLDI@redchip.com

CALIDI

BIOTHERAPEUTICS, INC.

CONSOLIDATED

BALANCE SHEETS

(In

thousands, except for par value data)

December 31,

2025

2024

ASSETS

CURRENT ASSETS

Cash

$ 5,600

$ 9,591

Prepaid expenses and other current assets

656

636

Total current assets

6,256

10,227

NONCURRENT ASSETS

Machinery and equipment, net

781

869

Operating lease right-of-use assets, net

1,682

2,934

Other noncurrent assets

138

152

TOTAL ASSETS

$ 8,857

$ 14,182

LIABILITIES AND TOTAL EQUITY

CURRENT LIABILITIES

Accounts payable

$ 595

$ 2,072

Related party accounts payable

Accrued expenses and other current liabilities

1,276

1,858

Related party accrued expenses and other current liabilities

530

480

Term notes payable, net of discount, including accrued interest

—

251

Related party term notes payable, net of discount, including accrued interest

—

2,702

Related party bridge loan payable, including accrued interest

—

223

Related party other current liability

—

638

Finance lease liability, current

111

Operating lease right-of-use liability, current

1,405

1,204

Total current liabilities

3,935

9,496

NONCURRENT LIABILITIES

Operating lease right-of-use liability, noncurrent

277

1,845

Finance lease liability, noncurrent

171

145

Promissory note

600

Warrant liability

107

119

Related party warrant liability

TOTAL LIABILITIES

5,098

12,214

TOTAL EQUITY

3,759

1,968

TOTAL LIABILITIES AND TOTAL EQUITY

$ 8,857

$ 14,182

CALIDI

BIOTHERAPEUTICS, INC.

CONSOLIDATED

STATEMENTS OF OPERATIONS

(In

thousands, except per share data)

Year Ended December 31,

2025

2024

OPERATING EXPENSES

Research and development

$ (9,737 )

$ (8,878 )

General and administrative

(10,503 )

(12,898 )

Total operating expense

(20,240 )

(21,776 )

Loss from operations

(20,240 )

(21,776 )

OTHER INCOME (EXPENSES), NET

Interest expense

(131 )

(372 )

Interest expense – related party

(76 )

(561 )

Change in fair value of other liabilities and derivatives

285

Change in fair value of other liabilities and derivatives – related party

Grant income

181

Gain on sale of investment in Nova Cell

244

—

Other income, net

103

Total other income (expenses), net

192

(419 )

LOSS BEFORE INCOME TAXES

(20,048 )

(22,195 )

Income tax provision

(15 )

(14 )

NET LOSS

$ (20,063 )

$ (22,209 )

Net loss attributable to noncontrolling interest

(157 )

(66 )

NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST

(19,906 )

(22,143 )

Deemed dividend on warrants

(5,673 )

(1,671 )

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

(25,579 )

(23,814 )

Net loss per share; basic and diluted

$ (5.95 )

$ (35.70 )

Weighted average common stock shares outstanding; basic and diluted

4,302

667

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (3080 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Mar. 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 27, 2026

Entity File Number

001-40789

Entity Registrant Name

CALIDI

BIOTHERAPEUTICS, INC.

Entity Central Index Key

0001855485

Entity Tax Identification Number

86-2967193

Entity Incorporation, State or Country Code

Entity Address, Address Line One

4475

Executive Drive

Entity Address, Address Line Two

Suite 200

Entity Address, City or Town

San

Diego

Entity Address, State or Province

Entity Address, Postal Zip Code

92121

City Area Code

(858)

Local Phone Number

794-9600

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $0.0001 per share

Trading Symbol

CLDI

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration